<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03923868</url>
  </required_header>
  <id_info>
    <org_study_id>IBIO-202</org_study_id>
    <nct_id>NCT03923868</nct_id>
  </id_info>
  <brief_title>D-0120 Safety and PK/PD Study in China</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multiple-administration, Multiple-dose, Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of D-0120 Tablets in Healthy Subjects and Hyperuricemia Patients in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InventisBio Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InventisBio Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a randomized, double-blind, placebo-controlled, multiple-administration, multiple-dose,&#xD;
      dose-escalating, phase Ib/IIa clinical study to evaluate the safety, tolerability, PK and PD&#xD;
      of D-0120 in healthy subjects and hyperuricemia patients (gout or asymptomatic) in China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects with treatment-related adverse events as assessed</measure>
    <time_frame>Day 1 - Day 28</time_frame>
    <description>Data will include clinical observations, ECG parameters, clinical chemistry and haematology and vital signs assessed as the number of subjects with treatment-related adverse events assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to observed Cmax (Tmax) for D-0120</measure>
    <time_frame>Day 1 - Day 28</time_frame>
    <description>Blood samples will be collected to assess plasma concentrations of D-0120 at a series of timepoints to derive Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) for D-0120</measure>
    <time_frame>Day 1 - Day 28</time_frame>
    <description>Blood samples will be collected to assess plasma concentrations of D-0120 at a series of timepoints to derive AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of D-0120</measure>
    <time_frame>Day 1 - Day 28</time_frame>
    <description>Blood samples will be collected to assess plasma concentrations of D-0120 at a series of timepoints to derive Cmax</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hyperuricemia or Gout</condition>
  <arm_group>
    <arm_group_label>dose escalation in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>dose escalation in hyperuricemia patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-0120</intervention_name>
    <description>D-0120 monotherapy dose escalation, oral, multiple dose for up to 28 days</description>
    <arm_group_label>dose escalation in healthy subjects</arm_group_label>
    <arm_group_label>dose escalation in hyperuricemia patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years old and ≤ 65 years old;&#xD;
&#xD;
          2. Phase Ib: fasting sUA in the morning of screening period (fasted after 8:00 pm on the&#xD;
             previous day) of healthy subjects meets the following requirement: 270 umol/l (4.5&#xD;
             mg/dL) ≤ sUA &lt;420 umol/l (7 mg/dL)&#xD;
&#xD;
             Phase IIa: hyperuricemia subjects should meet any of the following:&#xD;
&#xD;
          3. Subject's BMI range is 18.0~32.0 kg/m2 (inclusive);&#xD;
&#xD;
          4. Female subjects must be non-pregnant and non-lactating, surgically sterilized or ≥ 60&#xD;
             years old. Male subjects must be surgically sterilized or agree to practice sexual&#xD;
             abstinence;&#xD;
&#xD;
          5. Results of routine blood tests, blood biochemical tests and routine urine tests are&#xD;
             within the normal range or clinically insignificant as judged by the principle&#xD;
             investigator. Routine urine tests include normal urine creatinine, urine&#xD;
             protein/creatinine ratio. ECGs are within the normal range or clinically insignificant&#xD;
             as judged by the principle investigator.&#xD;
&#xD;
          6. Subjects have the ability to follow study and follow-up procedures.&#xD;
&#xD;
          7. Subjects have the ability to understand the study protocol and the risks involved, and&#xD;
             must provide signed informed consent form to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of significant metabolic, hematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, nervous, hepatic, renal, urinary, gastrointestinal, immune,&#xD;
             endocrine, psychiatric diseases, or clinical abnormalities that may pose excessive&#xD;
             risks to the subjects or affect outcome or study interpretation at the discretion of&#xD;
             the investigators;&#xD;
&#xD;
          2. Allergic constitution, or allergy to any drug used in the study or any ingredient of&#xD;
             study drug;&#xD;
&#xD;
          3. History of malignant tumors;&#xD;
&#xD;
          4. Subjects with positive results of any of the following items: screening hepatitis C&#xD;
             antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), hepatitis B surface&#xD;
             antigen (HBsAg) and treponema pallidum (only for phase Ib healthy subjects);&#xD;
&#xD;
          5. Urinary calculi confirmed by B-ultrasound during screening period;&#xD;
&#xD;
          6. Myocardial infarction, angina pectoris, percutaneous transluminal coronary&#xD;
             angioplasty, coronary artery bypass grafting, cerebral infarction, cerebral&#xD;
             hemorrhage, subarachnoid hemorrhage or transient ischemic attack within 3 months prior&#xD;
             to screening;&#xD;
&#xD;
          7. Participation in clinical studies of any investigational drugs or medical devices&#xD;
             within 3 months prior to screening;&#xD;
&#xD;
          8. Major surgery within 3 months prior to randomization;&#xD;
&#xD;
          9. Any clinically significant acute diseases within one month prior to screening at the&#xD;
             discretion of the investigators;&#xD;
&#xD;
         10. Gout flare within 14 days prior to randomization;&#xD;
&#xD;
         11. Use of other uric acid-lowering drugs (allopurinol, febuxostat, probenecid,&#xD;
             benzbromarone) within 14 days prior to randomization;&#xD;
&#xD;
         12. Daily dose of aspirin &gt; 100 mg within 14 days before randomization;&#xD;
&#xD;
         13. Use of any diuretic within 14 days before randomization;&#xD;
&#xD;
         14. Use of any Chinese herbal medicine within 14 days before randomization;&#xD;
&#xD;
         15. History of drug abuse or alcohol abuse (for phase Ib healthy subjects, the screening&#xD;
             alcohol test and urine drug test are positive);&#xD;
&#xD;
         16. Any situation that may prevent the subject from completing the study or pose a&#xD;
             significant risk to the subject as considered by any investigator;&#xD;
&#xD;
         17. Any other situation that may pose excessive risks to the subject or affect outcome or&#xD;
             study interpretation as considered by any investigator;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhe Shi, PhD</last_name>
    <phone>+86 21-50663661</phone>
    <email>zhe.shi@inventisbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 04</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 04</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 03</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 03</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 07</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 07</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 01- The second affiliated hospital of zhejiang university school of medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 01</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 06</name>
      <address>
        <city>Huzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 06</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 05</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 05</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>April 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2019</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

